Special Issue "Shiga Toxins: Pathogenicity and Therapeutic Applications"

A special issue of Toxins (ISSN 2072-6651). This special issue belongs to the section "Bacterial Toxins".

Deadline for manuscript submissions: closed (31 December 2020).

Special Issue Editor

Dr. Moo-Seung Lee
E-Mail Website1 Website2
Guest Editor
1. Department of Biomolecular Science, KRIBB School of Bioscience, Korea University of Science and Technology (UST), 127 Gajeong-ro, Yuseong-gu, Daejeon 34113, Korea
2. Environmental Diseases Research Center, Korea Research Institute of Bioscience and Biotechnology, 125 Gwahak-ro, Daejeon 34141, Korea
Interests: Bacterial toxins; Shiga toxin-producing E.coli; Shiga toxins; hemolytic uremic syndrome
Special Issues and Collections in MDPI journals

Special Issue Information

Dear Colleagues,

Shigellosis caused by Shiga toxin (Stx)-producing Shigella dysenteriae serotype 1 or Stx-producing Escherichia coli (STEC) continues to be a major public health threat and is a particular concern because of the potential to develop life-threatening extra-intestinal complications, such as acute renal failure (hemolytic uremic syndrome; HUS), and CNS complications, such as seizures, paralysis, and death. Once Shiga toxins (Stxs) are internalized following the toxin-receptor binding on host cellular surface, they are trafficked into the Golgi apparatus and to the ER in a retrograde manner to enter the host cell cytosol, leading to various host cellular responses, including protein synthesis inhibition, apoptosis through ER stress, autophagy, and inflammation. Distinct investigations on host cell signaling responses activated by Stxs as multifunctional proteins are necessary to identify novel targets for intervention in pathogenesis. Moreover, many studies present compelling and strong evidence regarding therapeutic applications to target particular diseases, such as tumors, by engineering the toxins.

At the molecular, cellular or clinical level, an improved understanding of the pathogenesis of the diseases’ bacillary dysentery and hemorrhagic colitis, and the subsequent development of extra-intestinal/extrarenal complications caused by STEC, will be necessary to develop effective protective and interventional therapies to treat patients infected with the organism.

This Special Issue of Toxins will focus on recent advances to consider unexplored mechanisms of STEC-mediated pathogenesis, current therapeutic applications or STEC genetics contributing to pathogenicity.

Prof. Dr. Moo-Seung Lee
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Toxins is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Shiga toxins
  • Shiga toxin-producing Shigella species
  • Shiga toxin-producing Escherichia coli
  • hemolytic uremic syndrome
  • Shiga toxins-mediated pathogenesis
  • cancer therapeutics
  • toxin engineering

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Article
Baicalein Inhibits Stx1 and 2 of EHE: Effects of Baicalein on the Cytotoxicity, Production, and Secretion of Shiga Toxins of Enterohaemorrhagic Escherichia coli
Toxins 2019, 11(9), 505; https://0-doi-org.brum.beds.ac.uk/10.3390/toxins11090505 - 29 Aug 2019
Cited by 2 | Viewed by 1502
Abstract
Shiga toxin-producing enterohaemorrhagic Escherichia coli (EHEC) O157:H7 is an important foodborne pathogen. Baicalein (5,6,7-trihydroxylflavone), a flavone isolated from the roots of Scutellaria baicalensis, is considered as a potential antibacterial agent to control foodborne pathogens. Among seven compounds selected by in silico screening [...] Read more.
Shiga toxin-producing enterohaemorrhagic Escherichia coli (EHEC) O157:H7 is an important foodborne pathogen. Baicalein (5,6,7-trihydroxylflavone), a flavone isolated from the roots of Scutellaria baicalensis, is considered as a potential antibacterial agent to control foodborne pathogens. Among seven compounds selected by in silico screening of the natural compound database, baicalein inhibited the cytotoxicity of both Shiga toxins 1 and 2 (Stx1 and Stx2) against Vero cells after pretreatment at 0.13 mmol/L. In addition, baicalein reduced the susceptibility of Vero cells to both Stx1 and Stx2. Real-time qPCR showed that baicalein increased transcription of stx1 but not of stx2. However, baicalein had no effects on production or secretion of Stx1 or Stx2. Docking models suggested that baicalein formed a stable structure with StxB pentamer with low intramolecular energy. The results demonstrate that inhibitory activity of baicalein against the cytotoxicity of both Stx1 and Stx2 might be due to of the formation of a binding structure inside the pocket of the Stx1B and Stx2B pentamers. Full article
(This article belongs to the Special Issue Shiga Toxins: Pathogenicity and Therapeutic Applications)
Show Figures

Figure 1

Back to TopTop